Home
News
Latest News
People Moves
Business Briefs
Newsletters
Features
Features
Reprints
Surveys
Editorial Calendar
Web Exclusives
Issue Archive
Events
MM&M Awards 2012
txt4pharma
MM&M Virtual Summit
Webcasts
Leadership Exchanges
Whitepapers
Directories
Creative Portfolio
Mobile Guide
Interactive Guide
Pharmaceutical Marketers Directory
MM&M Service Directory
Agency Gallery
Direct Marketing Showcase
Medical Education Review
Sales Force Listings
Jobs
About Us
Subscriber Services
Contact Us
Media Information
Editorial Advisory Board
Drug Info
New Drug Dossier
Drug Database
Subscribe
Order Now
Subscriber Services
Newsletters
RSS
|
Login
|
Register
MMM
>
News
> Generic form of Wellbutrin XL approved
Washington Insider
Generic form of Wellbutrin XL approved
James G. Dickinson
February 01, 2007
Print
Email
Reprint
Permissions
Text:
A
|
A
|
A
More News
Did FDA's Vytorin warning negatively impact health outcomes?
Roundtable outlines path for publisher, pharma credibility
No-see docs are know-nothings when it comes to new drug info, study suggests
E-prescriptions boost adherence data
How CDC's hep.-C testing advice benefits drugmakers now
The first US generic form of GlaxoSmithKline's Wellbutrin XL has been approved by the FDA. Anchen Pharmaceuticals' bupropion HCl extended-release tablets are available in 150 mg and 300 mg strengths.
From the February 2007 Issue of MMM
Please enable JavaScript to view the
comments powered by Disqus.
Video Exclusive
Web Exclusives
Five industry experts advise specialty pharma company on digital strategy
April 20, 2012
Specialty pharma company POZEN assembled a crack team of experts to help shape its digital strategy. Not only did POZEN share with us the text from their contributions, but you can watch exclusive video clips of their valuable perspectives right here.
MM&M Awards 2011 HIghlights
The Best MM&M Awards Ever!
MAHF Ceremony 2012
Photos from the Medical Advertising Hall of Fame Awards ceremony
Most Popular
Most Emailed
Most Recent
Goodbye Plavix, hello competition
Sales forces shrank in 2011, but not everywhere
Pharmas are from Mars, Payers are from Venus
No-see docs are know-nothings when it comes to new drug info, study suggests
Study: Young Latinas are key decision makers, prefer English
How CDC's hep.-C testing advice benefits drugmakers now
Indian conglomerate buys Manhattan Research parent for $635m
PhRMA's Washington wish list
E-prescriptions boost adherence data
Roundtable outlines path for publisher, pharma credibility
Study: Young Latinas are key decision makers, prefer English
No-see docs are know-nothings when it comes to new drug info, study suggests
Pharmas are from Mars, Payers are from Venus
Indian conglomerate buys Manhattan Research parent for $635m
E-prescriptions boost adherence data
Goodbye Plavix, hello competition
Sales forces shrank in 2011, but not everywhere
How CDC's hep.-C testing advice benefits drugmakers now
PhRMA's Washington wish list
Roundtable outlines path for publisher, pharma credibility
Did FDA's Vytorin warning negatively impact health outcomes?
Roundtable outlines path for publisher, pharma credibility
No-see docs are know-nothings when it comes to new drug info, study suggests
E-prescriptions boost adherence data
How CDC's hep.-C testing advice benefits drugmakers now
PhRMA's Washington wish list
Study: Young Latinas are key decision makers, prefer English
Pharmas are from Mars, Payers are from Venus
Goodbye Plavix, hello competition
Indian conglomerate buys Manhattan Research parent for $635m
Popular Topics
Acquisition
Adherence
App
Celebrity
Clinical Trial
Co-Marketing
Conflict Of Interest
Diabetes
Diagnostics
Digital
Direct To Consumer (DTC)
Disease Awareness
Downsize
Education & Awareness
FDA
Government
Guidance
Health Plans
HMOs
Hospitals
Insurers
Law
Marketing Research
Medical Journal
Sales Force